AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29595449 — intervention group
Group type: COMPARATOR
Intervention: Control (no routine oxygen supplementation unless required for reasons other than stroke)
Number of subjects: 8003
Study 27471803 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoom2 25% HP with UV light
Number of subjects: 28
Study 27471803 — intervention group
Group type: EXPERIMENTAL
Intervention: Beaming White 36% HP with LED light
Number of subjects: 28
Study 27471803 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 28
Study 25199313 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling
Number of subjects: 226
Study 25199313 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (1 mg x kg(‐1))
Number of subjects: 226
Study 25199313 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (1 mg x kg(‐1)) plus Cooling
Number of subjects: 226
Study 25199313 — intervention group
Group type: COMPARATOR
Intervention: Control (no prophylactic intervention)
Number of subjects: 226
Study 22302296 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg NTG skin spray
Number of subjects: 10
Study 22302296 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline
Number of subjects: 10
Study 20363999 — intervention group
Group type: EXPERIMENTAL
Intervention: CO(2) therapy in addition to routine methods (surgical and/or chemical debridement, advanced dressings)
Number of subjects: 70
Study 20363999 — intervention group
Group type: COMPARATOR
Intervention: Routine methods alone (surgical and/or chemical debridement, advanced dressings)
Number of subjects: 70
Study 17302075 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthetic gas extractor
Number of subjects: 24
Study 17302075 — intervention group
Group type: COMPARATOR
Intervention: No extractor
Number of subjects: 24
Study 14578611 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/day)
Number of subjects: 17
Study 14578611 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin (10 mg/day)
Number of subjects: 17
Study 10732656 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine 37.5 mg b.i.d. (increased to 75 mg b.i.d. from day 15)
Number of subjects: 147
Study 10732656 — intervention group
Group type: COMPARATOR
Intervention: Sertraline 50 mg once daily (remained at 50 mg b.i.d. from day 15)
Number of subjects: 147
Study 8887985 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan (TRP) depletion
Number of subjects: 7
Study 8887985 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1/4 strength preparation of an amino acid mixture)
Number of subjects: 7
Study 1396891 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambroxol
Number of subjects: 148
Study 1396891 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study 3964710 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem and propranolol (120 mg diltiazem and 160 mg propranolol)
Number of subjects: 15
Study 3964710 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 3964710 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem and propranolol
Number of subjects: 15
Study 31765046 — intervention group
Group type: EXPERIMENTAL
Intervention: elbasvir (50 mg)/grazoprevir (100 mg) for 8 weeks
Number of subjects: 117
Study 31765046 — intervention group
Group type: EXPERIMENTAL
Intervention: elbasvir (50 mg)/grazoprevir (100 mg) for 12 weeks
Number of subjects: 117
Study 31765046 — intervention group
Group type: EXPERIMENTAL
Intervention: elbasvir (50 mg)/grazoprevir (100 mg) for 12 weeks (treatment-experienced)
Number of subjects: 117
Study 31675351 — intervention group
Group type: EXPERIMENTAL
Intervention: Occipital cryoneurolysis
Number of subjects: 52
Study 31675351 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid (1 mL methylprednisolone 40 mg/mL) + local anaesthetic (1 mL bupivacaine 5 mg/mL)
Number of subjects: 52
Study 28492701 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term intensive training (SIT)
Number of subjects: 49
Study 28492701 — intervention group
Group type: COMPARATOR
Intervention: Conventional training (CT)
Number of subjects: 49
Study 26330583 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal-on-metal (MoM) bearing surface
Number of subjects: 45
Study 26330583 — intervention group
Group type: COMPARATOR
Intervention: Metal-on-polyethylene (MoP) bearing surface
Number of subjects: 45
Study 23756080 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-second benzocaine spray before upper endoscopy
Number of subjects: 401
Study 23756080 — intervention group
Group type: COMPARATOR
Intervention: No spray (control group)
Number of subjects: 401
Study 21629111 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical negative pressure therapy
Number of subjects: 24
Study 21629111 — intervention group
Group type: COMPARATOR
Intervention: Conventional dressing therapy with sodium hypochlorite
Number of subjects: 24
Study 19793724 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diamorphine (0.1 mg/kg)
Number of subjects: 24
Study 19793724 — intervention group
Group type: COMPARATOR
Intervention: Intranasal diamorphine (0.1 mg/kg)
Number of subjects: 24
Study 16966534 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine (3 to 6 mg/day)
Number of subjects: 157
Study 16966534 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study 16966534 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 157
Study 15376499 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone treatment
Number of subjects: 0
Study 11576376 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH (0.125 IU/kg for the first four weeks, then 0.25 IU/kg) three times a week after each dialysis session
Number of subjects: 19
Study 11576376 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH
Number of subjects: 19
Study 11576376 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 9701294 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (100 mg)
Number of subjects: 68
Study 9701294 — intervention group
Group type: COMPARATOR
Intervention: Hydrocodone-acetaminophen (5 mg hydrocodone with 500 mg acetaminophen)
Number of subjects: 68
Study 8181137 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (0.1 mg/kg)
Number of subjects: 10
Study 8181137 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 10
Study 2597854 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural family intervention
Number of subjects: 0
Study 2597854 — intervention group
Group type: COMPARATOR
Intervention: Short educational programme or routine treatment (Control)
Number of subjects: 0
Study 52767 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 cm of positive end-expiratory pressure (P.E.E.P.)
Number of subjects: 25
Study 52767 — intervention group
Group type: COMPARATOR
Intervention: No P.E.E.P.
Number of subjects: 25
Study 30281141 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser treatment followed by topical application of sodium stibogluconate
Number of subjects: 20
Study 30281141 — intervention group
Group type: COMPARATOR
Intervention: Intralesional injections of sodium stibogluconate
Number of subjects: 20
Study 28506006 — intervention group
Group type: EXPERIMENTAL
Intervention: Backpack load of 10% body weight (BW)
Number of subjects: 30
Study 28506006 — intervention group
Group type: EXPERIMENTAL
Intervention: Backpack load of 15% body weight (BW)
Number of subjects: 30
Study 28506006 — intervention group
Group type: COMPARATOR
Intervention: No backpack load
Number of subjects: 30
Study 28506006 — intervention group
Group type: EXPERIMENTAL
Intervention: Backpack load of 5% body weight (BW)
Number of subjects: 30
Study 26137916 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 0
Study 26137916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24100091 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based decision aid (n=124), used by 38.7% (48/124) of patients, with full functionality utilized by most users.
Number of subjects: 250
Study 24100091 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group, n=126).
Number of subjects: 250
Study 21447654 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine
Number of subjects: 20
Study 21447654 — intervention group
Group type: EXPERIMENTAL
Intervention: ATP
Number of subjects: 20
Study 21447654 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 20
Study 21447654 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyramine infusion during exercise
Number of subjects: 20
Study 21447654 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined ATP and tyramine infusions
Number of subjects: 20
Study 21447654 — intervention group
Group type: COMPARATOR
Intervention: Acetylcholine
Number of subjects: 20
Study 18331374 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich drink (400 ml, 12.5%) with paracetamol 1.5 g
Number of subjects: 25
Study 18331374 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 25
Study 16861254 — intervention group
Group type: EXPERIMENTAL
Intervention: Community hospital care
Number of subjects: 220
Study 16861254 — intervention group
Group type: COMPARATOR
Intervention: District general hospital care
Number of subjects: 220
Study 12742329 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive management
Number of subjects: 694
Study 12742329 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 694
Study 11410122 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenomedullin (AM) infusion (4 pmol.min(‐1).kg(‐1))
Number of subjects: 7
Study 11410122 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle - hemaccel)
Number of subjects: 7
Study 9390695 — intervention group
Group type: EXPERIMENTAL
Intervention: New antiepileptic drugs and nonpharmacologic treatments
Number of subjects: 0
Study 8430049 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal delivery of diclofenac sodium from a prototype hydrogel
Number of subjects: 0
Study 8430049 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (i.v.) infusion of diclofenac sodium
Number of subjects: 0
Study 3168444 — intervention group
Group type: EXPERIMENTAL
Intervention: Full breastfeeding with high nursing frequency (8+ suckling episodes per 24 h)
Number of subjects: 676
Study 3168444 — intervention group
Group type: COMPARATOR
Intervention: Supplementation (11% by end of 3rd month, 48% by end of 6th month)
Number of subjects: 676
Study 3168444 — intervention group
Group type: EXPERIMENTAL
Intervention: High nursing frequency
Number of subjects: 676
Study 3168444 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and parity
Number of subjects: 676
Study 3168444 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal weight, ponderal index, infant sex, birth weight, growth rate
Number of subjects: 676
Study 3168444 — intervention group
Group type: EXPERIMENTAL
Intervention: Full breastfeeding with high nursing frequency
Number of subjects: 676
Study 29447248 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported park prescription (physician counseling, maps, journal, pedometer, phone and text reminders, three weekly family nature outings with free transportation, food, and programming)
Number of subjects: 78
Study 29447248 — intervention group
Group type: COMPARATOR
Intervention: Independent park prescription (physician counseling, maps, journal, pedometer)
Number of subjects: 78
Study 29447248 — intervention group
Group type: EXPERIMENTAL
Intervention: Park visits per week (self-reported and journaling)
Number of subjects: 78
Study 28281728 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional flow reserve (FFR) measurement
Number of subjects: 359
Study 28281728 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual assessment by observer O1
Number of subjects: 359
Study 28281728 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual assessment by observer O2
Number of subjects: 359
Study 28281728 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual assessment by observer O3
Number of subjects: 359
Study 28281728 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of FFR results to observers' decisions
Number of subjects: 359
Study 28281728 — intervention group
Group type: EXPERIMENTAL
Intervention: Kappa analysis for agreement between observers and FFR
Number of subjects: 359
Study 28281728 — intervention group
Group type: EXPERIMENTAL
Intervention: Kappa agreement analysis between observers
Number of subjects: 359
Study 25287298 — intervention group
Group type: EXPERIMENTAL
Intervention: Together at School intervention program
Number of subjects: 79
Study 25287298 — intervention group
Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 79
Study 23176318 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy eSkills Training Online resource
Number of subjects: 0
Study 23176318 — intervention group
Group type: COMPARATOR
Intervention: Usual teaching only
Number of subjects: 0
Study 19910619 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (300 mg before TKA and 150-50 mg twice daily for 14 days after TKA)
Number of subjects: 240
Study 19910619 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 240
Study 19910619 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 18303706 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingent reinforcement (CR)
Number of subjects: 181
Study 18303706 — intervention group
Group type: EXPERIMENTAL
Intervention: CR plus nicotine patch (21 mg, CR+NRT) for 16 weeks
Number of subjects: 181
Study 18303706 — intervention group
Group type: COMPARATOR
Intervention: Minimal intervention, self‐quit control group
Number of subjects: 181
Study 16227041 — intervention group
Group type: EXPERIMENTAL
Intervention: Afternoon exercise session on a treadmill
Number of subjects: 50
Study 16227041 — intervention group
Group type: COMPARATOR
Intervention: Sedentary day
Number of subjects: 50
Study 12004315 — intervention group
Group type: EXPERIMENTAL
Intervention: 308-nm xenon-chloride excimer laser, treated 3 times a week for a maximum of 12 treatments
Number of subjects: 18
Study 12004315 — intervention group
Group type: COMPARATOR
Intervention: Untreated control patches
Number of subjects: 18
Study 10207634 — intervention group
Group type: EXPERIMENTAL
Intervention: 81 mg of aspirin per day for 3 months
Number of subjects: 0
Study 10207634 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet for 3 months (washout period)
Number of subjects: 0
Study 7829623 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms potassium iodide (KI)/day
Number of subjects: 180
Study 7829623 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms iodide plus 100 micrograms L‐T4/day
Number of subjects: 180
Study 7829623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 2199628 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam (2 g i.m.)
Number of subjects: 162
Study 2199628 — intervention group
Group type: COMPARATOR
Intervention: Placebo (4 ml lidocaine 2%)
Number of subjects: 162
Study 435015 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants
Number of subjects: 5
Study 435015 — intervention group
Group type: COMPARATOR
Intervention: Lithium carbonate
Number of subjects: 5
Study 31129372 — intervention group
Group type: EXPERIMENTAL
Intervention: SHHC‐2.0 curriculum (intervention group)
Number of subjects: 0
Study 31129372 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention (control group)
Number of subjects: 0
Study 28097016 — intervention group
Group type: EXPERIMENTAL
Intervention: Training intervention in community pharmacies
Number of subjects: 621
Study 28097016 — intervention group
Group type: COMPARATOR
Intervention: Usual practice in community pharmacies
Number of subjects: 621
Study 25558983 — intervention group
Group type: EXPERIMENTAL
Intervention: s.c. fentanyl
Number of subjects: 156
Study 25558983 — intervention group
Group type: EXPERIMENTAL
Intervention: i.n. fentanyl
Number of subjects: 156
Study 25558983 — intervention group
Group type: COMPARATOR
Intervention: i.m. pethidine
Number of subjects: 156
Study 23051740 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II receptor blocker (ARB) plus calcium channel blocker (CCB) combination
Number of subjects: 1164
Study 23051740 — intervention group
Group type: COMPARATOR
Intervention: High-dose angiotensin II receptor blocker (ARB)
Number of subjects: 1164
Study 21887284 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 42418
Study 21887284 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril
Number of subjects: 42418
Study 19087077 — intervention group
Group type: EXPERIMENTAL
Intervention: H Pipelle
Number of subjects: 60
Study 19087077 — intervention group
Group type: COMPARATOR
Intervention: Pipelle
Number of subjects: 60
Study 17893454 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiberoptic intubation with a flexible silicone tube without neuromuscular blocking agents
Number of subjects: 270
Study 17893454 — intervention group
Group type: COMPARATOR
Intervention: Orotracheal intubation with a polyvinyl chloride tube after induction with neuromuscular blocking agents
Number of subjects: 270
Study 17893454 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 270
Study 16322373 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive cardiovascular stress (PCS) protocol
Number of subjects: 26
Study 16322373 — intervention group
Group type: EXPERIMENTAL
Intervention: Active gravitational training (with bicycle work)
Number of subjects: 26
Study 16322373 — intervention group
Group type: COMPARATOR
Intervention: Passive gravitational training (without work)
Number of subjects: 26
Study 16322373 — intervention group
Group type: EXPERIMENTAL
Intervention: PCS exposure
Number of subjects: 26
Study 12846708 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 10 microgram.kg‐1
Number of subjects: 120
Study 12846708 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 20 microgram.kg‐1
Number of subjects: 120
Study 12846708 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 30 microgram.kg‐1
Number of subjects: 120
Study 12846708 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 40 microgram.kg‐1
Number of subjects: 120
Study 12846708 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 50 microgram.kg‐1
Number of subjects: 120
Study 12846708 — intervention group
Group type: COMPARATOR
Intervention: No caudal block (group C)
Number of subjects: 120
Study 10329078 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin (low molecular weight heparin)
Number of subjects: 293
Study 8952122 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific subtype of social phobia
Number of subjects: 0
Study 8952122 — intervention group
Group type: COMPARATOR
Intervention: Generalized subtype of social phobia
Number of subjects: 0
Study 8952122 — intervention group
Group type: EXPERIMENTAL
Intervention: Social phobics with comorbid disorders
Number of subjects: 0
Study 8952122 — intervention group
Group type: COMPARATOR
Intervention: Social phobics without comorbid disorders
Number of subjects: 0
Study 1826285 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 18
Study 1826285 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 6803977 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine (1 mg/kg or 4 mg/kg either by mouth or intramuscularly)
Number of subjects: 46
Study 6803977 — intervention group
Group type: COMPARATOR
Intervention: Control group (12 patients)
Number of subjects: 46
Study 6803977 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 46
Study 30900581 — intervention group
Group type: EXPERIMENTAL
Intervention: AL‐Scan
Number of subjects: 80
Study 30900581 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenstar LS900
Number of subjects: 80
Study 30900581 — intervention group
Group type: EXPERIMENTAL
Intervention: Galilei
Number of subjects: 80
Study 30900581 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound Pachymetry (UP)
Number of subjects: 80
Study 30900581 — intervention group
Group type: COMPARATOR
Intervention: AL‐Scan vs UP
Number of subjects: 80
Study 30900581 — intervention group
Group type: COMPARATOR
Intervention: Lenstar LS900 vs UP
Number of subjects: 80
Study 30900581 — intervention group
Group type: COMPARATOR
Intervention: AL‐Scan vs Lenstar LS900
Number of subjects: 80
Study 30900581 — intervention group
Group type: COMPARATOR
Intervention: Galilei vs other methods
Number of subjects: 80
Study 28144797 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-explanation of pathophysiological mechanisms (n=20)
Number of subjects: 39
Study 28144797 — intervention group
Group type: COMPARATOR
Intervention: No self-explanation (n=19)
Number of subjects: 39
Study 25774995 — intervention group
Group type: EXPERIMENTAL
Intervention: Incongruent selective attention items
Number of subjects: 0
Study 25774995 — intervention group
Group type: COMPARATOR
Intervention: Congruent selective attention items
Number of subjects: 0
Study 23462262 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin 4 g before skin incision and 2 g during skin closure
Number of subjects: 8
Study 22039966 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily multivitamin supplement
Number of subjects: 255
Study 22039966 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255
Study 18270356 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 cycles of etoposide and cisplatin
Number of subjects: 186
Study 18270356 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 cycles of cisplatin, etoposide, and bleomycin
Number of subjects: 186
Study 18270356 — intervention group
Group type: COMPARATOR
Intervention: 4 cycles of bleomycin, etoposide, and cisplatin
Number of subjects: 186
Study 18270356 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (second- and third-line programs)
Number of subjects: 186
Study 15987880 — intervention group
Group type: EXPERIMENTAL
Intervention: Relational encoding of word stimuli prior to recency judgements
Number of subjects: 0
Study 15987880 — intervention group
Group type: EXPERIMENTAL
Intervention: Item-based processing of word stimuli prior to recency judgements
Number of subjects: 0
Study 15987880 — intervention group
Group type: EXPERIMENTAL
Intervention: Recognition of individual words (familiarity/recency judgements)
Number of subjects: 0
Study 12904425 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR assay for identification of Staphylococcus aureus and determination of methicillin resistance
Number of subjects: 28